Home
Search
Study Topics
Glossary
|
|
|
|
|
A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chicken Pox)
.
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00130793 |
The purpose of this study is to determine whether the refrigerator-stable formulation of an investigational vaccine has a comparable immune response (the body?s ability to protect against disease) and safety profile to that of the freezer-stable formulation of the vaccine.
Condition | Intervention | Phase |
---|---|---|
Herpes Zoster |
Biological: Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation Biological: Comparator: zoster vaccine live (Oka/Merck) frozen formulation |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Bio-equivalence Study |
Official Title: | A Double-Blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of a Refrigerator-Stable Formulation of Zoster Vaccine Live (Oka/Merck) |
Enrollment: | 368 |
Study Start Date: | August 2005 |
Study Completion Date: | January 2006 |
Primary Completion Date: | December 2005 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
zoster vaccine live (Oka/Merck) refrigerated formulation
|
Biological: Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation
1 dose of 0.65mL/dose subcutaneous injection of zoster vaccine live (Oka/Merck) refrigerated formulation at Day 1
|
2: Active Comparator
zoster vaccine live (Oka/Merck) frozen formulation
|
Biological: Comparator: zoster vaccine live (Oka/Merck) frozen formulation
1 dose of 0.65mL/dose subcutaneous injection of zoster vaccine live (Oka/Meck) frozen formulation at Day 1
|
The duration of treatment is 4 weeks.
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences ) |
Study ID Numbers: | 2005_035, V211-010 |
Study First Received: | August 11, 2005 |
Last Updated: | February 5, 2009 |
ClinicalTrials.gov Identifier: | NCT00130793 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Virus Diseases Herpes Zoster Chickenpox DNA Virus Infections Herpesviridae Infections |
Virus Diseases Herpes Zoster DNA Virus Infections Herpesviridae Infections |